Loading…
Unusual conglomerate combining VITAS Healthcare hospice care with Roto-Rooter plumbing and drain-cleaning services.
Unusual conglomerate combining VITAS Healthcare hospice care with Roto-Rooter plumbing and drain-cleaning services.
Is paid by Medicare, mostly under a fixed daily rate per hospice patient, so VITAS's income follows patient days and government payment rules. Roto-Rooter is paid directly by homeowners and businesses per job, through company-owned branches and franchisees. The two businesses are unrelated, and VITAS is the larger.
Moat: narrow (brand, scale, installed base). Leading hospice provider scale and the dominant national plumbing-service brand, an unusual but durable combo.
Headquarters: Cincinnati, Ohio, US · Founded: 1970 · Employees: 15,811
Size Chemed (CHE) is a United States Health Care company (Hospital/Nursing Management) with a market value of $6.87B, the 970th largest of 3,117 United States companies the cockpit tracks. Shares closed at $528.05 on 6 Nov 2026.
Performance Over six months the shares gained 24.5%, against +5.1% for the median peer and -1.1% for the United States market (cap-weighted) — 6th highest of 19 in its peer set.
Growth Revenue grew 5.2% over the last twelve months (peer median +11.0%); the operating margin is 14.0% (peer median 12.7%).
Valuation It trades at 19.5× forward earnings against a peer median of 40.8× (6th cheapest of 19).
Price implies For today's price to make sense, revenue must grow about 2% a year for seven years (Req g). Recent delivered growth is +4%, so the hurdle is -2 pp: the price already allows for a slowdown.
Capital Return on invested capital runs 16.9 points above its cost of capital (7.2% WACC).
Short interest Short interest is 5.2% of the free float (15 Oct 2026).
Next results Next results expected around 25 Feb 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | $2.66B | $2.53B | $2.43B | $2.26B | $2.13B |
| Revenue growth | — | +4% | +7% | +6% | — |
| Gross profit | $825M | $758M | $791M | $738M | $706M |
| EBITDA | $441M | $406M | $436M | $404M | $406M |
| Net income | $282M | $265M | $302M | $273M | $250M |
| Free cash flow | $295M | $325M | $368M | $273M | $253M |
| Capital expenditure | $67.7M | $62.8M | $49.5M | $56.9M | $57.3M |
| Total debt | $410M | $155M | $141M | $155M | $247M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g |
|---|---|---|---|---|---|---|
| Chemed CHE | $6.87B | +24% | +5% | 14% | 19.5× | 2.4% |
| Encompass Health EHC | $13.5B | +30% | +9% | 18% | 20.5× | 5.6% |
| Addus HomeCare ADUS | $2.32B | +25% | +12% | 11% | 16.6× | 4.9% |
| Pennant PNTG | $1.27B | +1% | +38% | 6% | 24.0× | 21.1% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | CHE | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +6.0% | +4.8% | 10th highest of 20 |
| 6-month return | +24.5% | +5.1% | 6th highest of 19 |
| Distance from 52-week high | -6.1% | -15.8% | 6th highest of 20 |
| Revenue growth (TTM) | +5.2% | +11.0% | 6th lowest of 20 |
| Operating margin | 14.0% | 12.7% | 9th highest of 20 |
| Forward P/E | 19.5× | 40.8× | 6th cheapest of 19 |
| Growth the price implies (Req g, 7 yrs) | 2.4% | 13.8% | 3rd least demanding of 18 |
| Growth delivered (Del g) | +4.0% | +9.7% | 4th lowest of 18 |
| Hurdle (Req g minus delivered) | -1.6 pp | +2.7 pp | 7th least demanding of 18 |
| ROIC minus cost of capital | +16.9 pp | -0.3 pp | highest of 20 |
| EV / EBITDA | 16.4× | 22.2× | 8th cheapest of 17 |
| Net debt / EBITDA | 0.8× | 2.4× | 2nd least indebted of 17 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Chemed CHE | United States | $6.87B | +24% | +5% | 14% | 19.5× | 2.4% | +4.0% |
| Aster DM Quality Care ASTERDM.NS | India | $6.57B | -3% | +16% | 14% | 49.6× | 55.3% | -11.6% |
| Fortis Healthcare FORTIS.NS | India | $6.13B | -19% | +18% | 17% | 45.0× | 41.0% | +17.9% |
| PACS PACS | United States | $7.87B | +48% | +11% | 8% | 19.2× | 7.6% | +29.7% |
| Ramsay Health Care RHC.AX | Australia | $8.87B | +52% | +4% | 5% | 32.4× | 14.3% | +8.3% |
| Manipal Health Enterprises MANIPALHOS.NS | India | $9.01B | n/a | +25% | 19% | 63.1× | 29.7% | +28.8% |
| Max Healthcare Institute MAXHEALTH.NS | India | $9.61B | -8% | +15% | 21% | 49.7× | 43.2% | +27.2% |
| Narayana Hrudayalaya NH.NS | India | $4.11B | +3% | +71% | 13% | 36.5× | 31.1% | +25.0% |
| Universal Health Services UHS | United States | $11.5B | +15% | +8% | 11% | 8.7× | -1.2% | +8.5% |
| Global Health MEDANTA.NS | India | $3.95B | +15% | +26% | 17% | 51.1× | n/a | n/a |
| Apollo Hospitals Enterprise APOLLOHOSP.NS | India | $12.8B | +8% | +19% | 12% | 49.3× | 32.2% | +19.0% |
| National HealthCare NHC | United States | $3.27B | +11% | +7% | -8% | n/a | 7.9% | +9.7% |
| Krishna Institute of Medical Sciences KIMS.NS | India | $3.21B | +2% | +31% | 12% | 70.0× | n/a | n/a |
| Surgery Partners SGRY | United States | $2.99B | +61% | +4% | 14% | 62.5× | 13.8% | +12.2% |
| Topchoice Medical 600763.SS | China | $2.51B | -11% | +7% | 26% | 26.7× | 13.6% | +6.9% |
| Ardent Health ARDT | United States | $2.44B | +71% | +3% | 4% | 14.5× | 4.0% | +8.7% |
| Brookdale Senior Living BKD | United States | $2.15B | -31% | -4% | 5% | 127.7× | 22.4% | -1.4% |
| Tenet Healthcare THC | United States | $22.5B | +49% | +6% | 17% | 14.0× | -1.2% | +3.9% |
| Huaxia Eye Hospital 301267.SZ | China | $1.92B | -16% | +2% | 15% | 24.7× | 3.8% | +10.4% |
| Extendicare EXE.TO | Canada | $1.87B | -9% | +31% | 9% | 19.4× | 11.2% | +8.5% |